CONTACT US

PHYSICIAN consultations, including second opinions, are fee-based.
INITIAL INQUIRY INTERNATIONAL PATIENT PROGRAM

SynerTri Immunotherapy:
Advancing Precision Immuno-Oncology

Decades of Immunotherapy Leadership.
Now Personalized to You.

As one of the early medical institutions to clinically implement WT1 dendritic cell vaccine therapy, Precision Clinic Group has developed extensive experience in dendritic cell-based immunotherapy. Today, we continue this clinical and scientific evolution through SynerTri Immunotherapy—our integrated precision strategy for patients with advanced cancer.

What began with dendritic cell vaccine technology has evolved into a broader precision immunotherapy platform tailored to the unique biology of each patient's cancer. Our approach is designed to optimize the conditions under which anti-cancer immunity can function effectively within the tumor microenvironment.

Featured in the WSJ Next Era Leaders article: "Taking Personalized Oncology to the Wider World."

PROVEN EXPERIENCE

6,500+

PATIENTS TREATED

One of the largest clinical experiences in dendritic cell vaccine therapy.

ACADEMIC HERITAGE

Built on technology developed at IMSUT, The University of Tokyo, and further advanced through the WT1 platform pioneered at Osaka University and Hokkaido University.

Global Leadership

World First medical institutions worldwide to clinically implement WT1 dendritic cell vaccine therapy.

A LEGACY OF INNOVATION

The Foundation of WT1 Dendritic Cell Therapy

Our clinical platform is rooted in advanced dendritic cell culture technology developed at The Institute of Medical Science, The University of Tokyo. By integrating the WT1 platform pioneered at Osaka University and Hokkaido University, we helped advance the early clinical application of WT1 dendritic cell vaccine therapy.

Why Experience Matters

Precision Clinic Group represents the continuation of decades of clinical and scientific development in cancer immunotherapy. With more than 6,500 treated cases, our experience supports a treatment platform shaped by long-term clinical practice and patient-centered care.

BEYOND WT1

Toward Individualized Precision Immuno-Oncology

Our platform has evolved beyond shared antigens alone. While WT1 remains an important component, our strategy now incorporates Tumor-Associated Antigens (TAAs), neoantigens, and autologous tumor tissue-derived antigens depending on the biological characteristics of each patient's cancer.

The Shift Toward Neoantigen-Guided Therapy

Using each patient's genomic information, we identify potential neoantigen targets and design personalized neoantigen-based dendritic cell vaccines when appropriate. This allows us to move toward a more individualized precision immunotherapy approach.

WHAT IS SYNERTRI IMMUNOTHERAPY?

An Integrated Precision Strategy

COMPONENT ROLE MECHANISM
COMPONENT: 01
— The Accelerator
 Dendritic Cell Vaccine Therapy Supports immune recognition of cancer-specific targets, including WT1, TAAs, neoantigens, and autologous tumor tissue-derived antigens.
COMPONENT: 02
— The Brake Release
 Immune Checkpoint Inhibitors Targets immune suppression pathways such as PD-1, PD-L1, and CTLA-4 that tumors may use to evade immune responses.
COMPONENT: 03
— The Switch
 Local Tumor-Directed Therapy Uses radiation therapy, particle therapy, BNCT, or cryotherapy to help stimulate biological signals associated with anti-tumor immune activation.

SynerTri is not a single drug or procedure. It is an integrated therapeutic platform designed to support effective anti-cancer immune activity within the tumor environment.

BUILT FOR PRECISION

Data-Driven Design

We believe cancer treatment should be guided by the molecular and immunological characteristics of each patient's tumor. By integrating genomic analysis with immunotherapy and local treatment strategies, we aim to develop more individualized approaches to cancer care.

THE TREATMENT JOURNEY

Practical Flow & Planning

Our process is designed for precision at every step.

01

Consultation & Planning

Tailoring the treatment strategy to your individual tumor profile.

02

Apheresis

Collecting immune cells from your blood for vaccine manufacturing.

03

Manufacturing & Storage

Preparing your personalized dendritic cell vaccine.

04

Administration

Typically administered once every 1–3 weeks.
Initial course: approximately 7 sessions over 4 months.

　

Neoantigen Note

For neoantigen-based vaccines, genomic analysis and vaccine preparation generally require approximately 2–3 months before administration.

FROM PIONEER RESEARCH TO PRECISION PLATFORM

Precision Clinic Group has participated in the clinical evolution of WT1 dendritic cell vaccine therapy. Today, this experience continues through SynerTri Immunotherapy—an integrated precision platform incorporating neoantigen-guided strategies and personalized immune-based approaches.

FOR INTERNATIONAL PATIENTS

We Welcome Patients from Around the World

Precision Clinic Group assists international patients with consultation coordination and treatment arrangements and can arrange multilingual support as needed throughout the treatment process.

INTERNATIONAL PATIENT SERVICES
SUGGESTED FAQ

Frequently Asked Questions

What is SynerTri Immunotherapy?

An integrated three-component strategy combining dendritic cell vaccine therapy, immune checkpoint inhibitors, and local tumor-directed therapy.

How does it differ from standard vaccine therapy?

It coordinates the vaccine with other treatments to ensure the immune system can strike the tumor effectively.

Is WT1 still used?

Yes. WT1 remains a core component and a key antigen within the SynerTri framework.

Do you offer neoantigen-based vaccines?

Yes. Custom-designed neoantigen approaches are utilized based on detailed genomic analysis.

What is the timeframe for international patients?

Preparation varies; for neoantigen-based vaccines, analysis and manufacturing typically take 2–3 months.

Publications

Publications and related research

Primary sources for the treatment approach we use: publications by physicians of our group, and peer-reviewed research on the technologies that make up our treatment. Items are listed as citations with links to the original articles; abstracts are not reproduced.

Publications by Precision Clinic Group(12)

Papers and presentations authored or co-authored by physicians of our group, including its predecessor clinics (Seren Clinic). Only items verified against PubMed, the publisher or the original document are listed.

  1. Case report2024
    Complete Cure of Inoperable Stage IV Locally Advanced Hypopharyngeal Squamous Cell Carcinoma by an Innovative Combination Cancer Immunotherapy Consisting of Radiation, Immune Checkpoint Inhibitors, and Dendritic Cell Vaccine
    Iwasaki T, Yazaki Y, Myojo T, Masuko T, Nishimura T. Cureus. 2024;16(9):e69429. PMID 39411614.
    Full textPubMedDOI
  2. Conference presentation2024
    Helper/killer hybrid epitope long peptide (H/K-HELP) cancer vaccine augments Th1-dependent CTL induction at tumor-draining lymph node to eradicate solid tumor: its application to develop an innovative combination cancer immunotherapy (iCCI)
    Iwasaki T, Yazaki Y, Masuko T, Nishimura T. Cancer Research. 2024;84(6_Supplement):Abstract 3741. AACR Annual Meeting 2024, San Diego, USA.
    AACR abstract
  3. Review2023
    Is the Abscopal Effect Obtained in Pancreatic and Biliary Tract Tumors?
    Shibamoto Y, Yazaki Y, Niwa M. Tan to Sui (The Biliary Tract & Pancreas). 2023;44(4):349–352. In Japanese.
    J-GLOBAL
  4. Clinical study2019
    Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1
    Ito Z, Kan S, Bito T, Horiuchi S, Akasu T, Yoshida S, Kajihara M, Hokari A, Saruta M, Yoshida N, Kobayashi M, Ohkusa T, Shimodaira S, Okamoto M, Sugiyama H, Koido S. Oncology. 2019;97(3):135–148. PMID 31216557.
    PubMedDOI
  5. Clinical study2018
    An Exploratory Study on the Anti-inflammatory Effects of Fucoidan in Relation to Quality of Life in Advanced Cancer Patients
    Takahashi H, Kawaguchi M, Kitamura K, Narumiya S, Kawamura M, Tengan I, Nishimoto S, Hanamure Y, Majima Y, Tsubura S, Teruya K, Shirahata S. Integrative cancer therapies. 2018;17(2):282–291. PMID 28627320.
    Full textPubMedDOI
  6. Clinical study2016
    Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis
    Takahashi H, Shimodaira S, Ogasawara M, Ota S, Kobayashi M, Abe H, Morita Y, Nagai K, Tsujitani S, Okamoto M, Suzuki Y, Nakanishi Y, Yonemitsu Y, DC Vaccine Study Group at the Japanese Society of Immunotherapy and Cell Therapy. Cancer Immunology, Immunotherapy. 2016;65(9):1099–1111. PMID 27448677.
    Full textPubMedDOI
  7. Clinical study2014
    Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis
    Kobayashi M, Shimodaira S, Nagai K, Ogasawara M, Takahashi H, Abe H, Tanii M, Okamoto M, Tsujitani S, Yusa S, Ishidao T, Kishimoto J, Shibamoto Y, Nagaya M, Yonemitsu Y, DC Vaccine Study Group at the Japan Society of Innovative Cell Therapy (J-SICT). Cancer Immunology, Immunotherapy. 2014;63(8):797–806. PMID 24777613.
    Full textPubMedDOI
  8. Case report2014
    Therapeutic effect of intratumoral injections of dendritic cells for locally recurrent gastric cancer: a case report
    Kobayashi M, Sakabe T, Chiba A, Nakajima A, Okamoto M, Shimodaira S, Yonemitsu Y, Shibamoto Y, Suzuki N, Nagaya M, DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT). World Journal of Surgical Oncology. 2014;12:390. PMID 25526950.
    Full textPubMedDOI
  9. Retrospective study2014
    The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer
    Kobayashi M, Chiba A, Izawa H, Yanagida E, Okamoto M, Shimodaira S, Yonemitsu Y, Shibamoto Y, Suzuki N, Nagaya M, DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT). Journal of Ovarian Research. 2014;7:48. PMID 25298213.
    Full textPubMedDOI
  10. Clinical study2013
    Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers
    Takahashi H, Okamoto M, Shimodaira S, Tsujitani S, Nagaya M, Ishidao T, Kishimoto J, Yonemitsu Y, DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT). European Journal of Cancer. 2013;49(4):852–859. PMID 23245331.
    PubMedDOI
  11. Retrospective study2013
    Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer
    Kobayashi M, Sakabe T, Abe H, Tanii M, Takahashi H, Chiba A, Yanagida E, Shibamoto Y, Ogasawara M, Tsujitani S, Koido S, Nagai K, Shimodaira S, Okamoto M, Yonemitsu Y, Suzuki N, Nagaya M, DC-vaccine study group at the Japan Society of Innovative Cell Therapy (J-SICT). Journal of Gastrointestinal Surgery. 2013;17(9):1609–1617. PMID 23877328.
    PubMedDOI
  12. Clinical study2013
    Immune-maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity-modulated radiation
    Shibamoto Y, Okamoto M, Kobayashi M, Ayakawa S, Iwata H, Sugie C, Mitsuishi Y, Takahashi H. Molecular and Clinical Oncology. 2013;1(4):649–654. PMID 24649223.
    Full textPubMedDOI
Related research on our technology(55 papers)

Peer-reviewed research by other institutions on the technologies that make up our treatment, and related immunological research. These studies were not conducted by our group. Same technology = the dendritic cell culture technology established at Tella Inc., a company founded by our group's founder Dr. Yazaki, including institutions and multicentre studies that used the same platform; Component technology / related research = the antigens (WT1, H/K-HELP), the adjuvant (OK-432), combination therapies or immunological mechanisms; Peripheral research = related authors or laboratories where use of the same culture technology has not been confirmed. Target diseases, antigens, combination treatments and manufacturing conditions differ between studies, and none of them demonstrates the efficacy of our current treatment on its own.

  1. Clinical studySame technology2025
    Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms' tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine
    Koido S, Taguchi J, Shimabuku M, Bito T, Morimoto S, Oji Y, Oka Y, Ito M, Shimizu Y, Ito Z, Uchiyama K, Saruta M, Sato N, Ohkusa T, Shimodaira S, Sugiyama H. Journal for ImmunoTherapy of Cancer. 2025;13(7):e011426. PMID 40744662.
    Full textPubMedDOI
  2. Clinical studySame technology2025
    Impact of Reduction in Myeloid-derived Suppressor Cells by Wilms' Tumor 1-targeted Dendritic Cell Vaccines on Clinical Outcomes in Acute Leukemia Patients
    Ogasawara M, Miyashita M, Yamagishi Y, Ota S. EJHaem. 2025;6(3):e70048. PMID 40370631.
    Full textPubMedDOI
  3. Clinical studySame technology2025
    Prognostic Impact of PD-1 Polymorphisms in Non-small Cell Lung Cancer Receiving Dendritic Cell Vaccination
    Ogasawara M, Miyashita M, Yamagishi Y, Ota S. Anticancer research. 2025;45(10):4295–4304. PMID 41006036.
    PubMedDOI
  4. Clinical studySame technology2025
    Combined immunotherapy employing Wilms' tumor 1 peptide-pulsed dendritic cells and hormone or chemotherapeutic agents in patients with metastatic castration resistant prostate cancer
    Ogasawara M, Miyashita M, Yamagishi Y, Ota S. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2025;29(4):568–576. PMID 40223232.
    PubMedDOI
  5. Clinical trialSame technology2024
    Dendritic cells pulsed with multifunctional Wilms' tumor 1 (WT1) peptides combined with multiagent chemotherapy modulate the tumor microenvironment and enable conversion surgery in pancreatic cancer
    Koido S, Taguchi J, Shimabuku M, Kan S, Bito T, Misawa T, Ito Z, Uchiyama K, Saruta M, Tsukinaga S, Suka M, Yanagisawa H, Sato N, Ohkusa T, Shimodaira S, Sugiyama H. Journal for ImmunoTherapy of Cancer. 2024;12(10):e009765. PMID 39384197.
    Full textPubMedDOI
  6. ReviewSame technology2024
    Wilms' tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives
    Ogasawara M. Human vaccines & immunotherapeutics. 2024;20(1):2296735. PMID 38148629.
    Full textPubMedDOI
  7. Clinical studySame technology2022
    Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia
    Ogasawara M, Miyashita M, Yamagishi Y, Ota S. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2022;26(3):537–547. PMID 35249263.
    PubMedDOI
  8. Clinical studySame technology2022
    Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory malignant lymphoma
    Ogasawara M, Miyashita M, Yamagishi Y, Ota S. Leukemia & lymphoma. 2022;63(7):1733–1737. PMID 35166650.
    PubMedDOI
  9. Clinical trialSame technology2021
    Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy
    Ota S, Miyashita M, Yamagishi Y, Ogasawara M. Human vaccines & immunotherapeutics. 2021;17(12):5563–5572. PMID 34919493.
    Full textPubMedDOI
  10. Clinical trialSame technology2021
    Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single-center phase I/II trial
    Ogasawara M, Miyashita M, Yamagishi Y, Ota S. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2021;25(4):415–424. PMID 33886156.
    PubMedDOI
  11. Clinical studySame technology2020
    Immunotherapy employing dendritic cell vaccination for patients with advanced or relapsed esophageal cancer
    Ogasawara M, Miyashita M, Yamagishi Y, Ota S. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2020;24(5):482–491. PMID 32524770.
    PubMedDOI
  12. Clinical studyComponent technology / related research2019
    Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines
    Hanada S, Tsuruta T, Haraguchi K, Okamoto M, Sugiyama H, Koido S. Human vaccines & immunotherapeutics. 2019;15(2):397–406. PMID 30230959.
    Full textPubMedDOI
  13. Clinical studyComponent technology / related research2019
    Clinical Significance of Tumor-Infiltrating T Cells and Programed Death Ligand-1 in Patients with Pancreatic Cancer
    Yoshida S, Ito Z, Suka M, Bito T, Kan S, Akasu T, Saruta M, Okamoto M, Kitamura H, Fujioka S, Misawa T, Akiba T, Yanagisawa H, Sugiyama H, Koido S. Cancer investigation. 2019;37(9):463–477. PMID 31490702.
    PubMedDOI
  14. Clinical trialSame technology2019
    Phase I/II Pilot Study of Wilms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer
    Ogasawara M, Miyashita M, Yamagishi Y, Ota S. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2019;23(3):279–288. PMID 31033141.
    PubMedDOI
  15. Clinical studyComponent technology / related research2018
    Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer
    Matsuda T, Takeuchi H, Sakurai T, Mayanagi S, Booka E, Fujita T, Higuchi H, Taguchi J, Hamamoto Y, Takaishi H, Kawakubo H, Okamoto M, Sunamura M, Kawakami Y, Kitagawa Y. Oncology Letters. 2018;16(1):1348–1356. PMID 29963201.
    Full textPubMedDOI
  16. Clinical trialSame technology2018
    WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study
    Yanagisawa R, Koizumi T, Koya T, Sano K, Koido S, Nagai K, Kobayashi M, Okamoto M, Sugiyama H, Shimodaira S. Anticancer research. 2018;38(4):2217–2225. PMID 29599342.
    PubMedDOI
  17. Clinical studySame technology2018
    Feasibility and Immune Response of WT1 Peptide Vaccination in Combination with OK-432 for Paediatric Solid Tumors
    Hirabayashi K, Yanagisawa R, Saito S, Higuchi Y, Koya T, Sano K, Koido S, Okamoto M, Sugiyama H, Nakazawa Y, Shimodaira S. Anticancer research. 2018;38(4):2227–2234. PMID 29599343.
    PubMedDOI
  18. Clinical studyComponent technology / related research2018
    Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma
    Kanai T, Ito Z, Oji Y, Suka M, Nishida S, Takakura K, Kajihara M, Saruta M, Fujioka S, Misawa T, Akiba T, Yanagisawa H, Shimodaira S, Okamoto M, Sugiyama H, Koido S. Oncology Letters. 2018;16(2):2682–2692. PMID 30008944.
    Full textPubMedDOI
  19. Clinical studySame technology2018
    Vaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses
    Ogasawara M, Miyashita M, Ota S. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2018;22(3):266–277. PMID 29851270.
    PubMedDOI
  20. 症例報告2017
    Dendritic cell vaccine therapy indicated a complete response for bladder cancer with a metastasis in lymph nodes, peritoneal dissemination and a subcutaneous metastasis: a report of a case
    福島岳志, 石井義之, 張益商. 泌尿器外科. 2017;30(11):1695–1698. In Japanese.
  21. Clinical studyComponent technology / related research2017
    Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma
    Fukuda K, Funakoshi T, Sakurai T, Nakamura Y, Mori M, Tanese K, Tanikawa A, Taguchi J, Fujita T, Okamoto M, Amagai M, Kawakami Y. Melanoma Research. 2017;27(4):326–334. PMID 28263240.
    PubMedDOI
  22. ReviewComponent technology / related research2017
    Significance of Wilms' tumor 1 antigen as a cancer vaccine for pancreatic cancer
    Koido S, Okamoto M, Kobayashi M, Shimodaira S, Sugiyama H. Discovery medicine. 2017;24(130):41–49. PMID 28950074.
    PubMed
  23. ReviewComponent technology / related research2016
    Dendritic cell-based cancer immunotherapy for colorectal cancer
    Kajihara M, Takakura K, Kanai T, Ito Z, Saito K, Takami S, Shimodaira S, Okamoto M, Ohkusa T, Koido S. World Journal of Gastroenterology. 2016;22(17):4275–4286. PMID 27158196.
    Full textPubMedDOI
  24. Clinical studyComponent technology / related research2016
    Comprehensive assessment of the prognosis of pancreatic cancer: peripheral blood neutrophil-lymphocyte ratio and immunohistochemical analyses of the tumour site
    Takakura K, Ito Z, Suka M, Kanai T, Matsumoto Y, Odahara S, Matsudaira H, Haruki K, Fujiwara Y, Saito R, Gocho T, Nakashiro K, Hamakawa H, Okamoto M, Kajihara M, Misawa T, Ohkusa T, Koido S. Scandinavian journal of gastroenterology. 2016;51(5):610–617. PMID 26679084.
    PubMedDOI
  25. ReviewComponent technology / related research2016
    Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer
    Koido S, Okamoto M, Shimodaira S, Sugiyama H. Immunotherapy. 2016;8(11):1309–1320. PMID 27993090.
    PubMedDOI
  26. ReviewComponent technology / related research2016
    Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer
    Kajihara M, Takakura K, Kanai T, Ito Z, Matsumoto Y, Shimodaira S, Okamoto M, Ohkusa T, Koido S. World Journal of Gastroenterology. 2016;22(18):4446–4458. PMID 27182156.
    Full textPubMedDOI
  27. ReviewSame technology2016
    Dendritic cell-based vaccine for pancreatic cancer in Japan
    Okamoto M, Kobayashi M, Yonemitsu Y, Koido S, Homma S. World journal of gastrointestinal pharmacology and therapeutics. 2016;7(1):133–138. PMID 26855819.
    Full textPubMedDOI
  28. Clinical trialSame technology2015
    Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer
    Mayanagi S, Kitago M, Sakurai T, Matsuda T, Fujita T, Higuchi H, Taguchi J, Takeuchi H, Itano O, Aiura K, Hamamoto Y, Takaishi H, Okamoto M, Sunamura M, Kawakami Y, Kitagawa Y. Cancer Science. 2015;106(4):397–406. PMID 25614082.
    Full textPubMedDOI
  29. Clinical trialSame technology2015
    Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma
    Sakai K, Shimodaira S, Maejima S, Udagawa N, Sano K, Higuchi Y, Koya T, Ochiai T, Koide M, Uehara S, Nakamura M, Sugiyama H, Yonemitsu Y, Okamoto M, Hongo K. Journal of Neurosurgery. 2015;123(4):989–997. PMID 26252465.
    PubMedDOI
  30. Basic researchComponent technology / related research2015
    Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy
    Masuko K, Wakita D, Togashi Y, Kita T, Kitamura H, Nishimura T. Immunology Letters. 2015;163(1):102–112. PMID 25479286.
    PubMedDOI
  31. Clinical studySame technology2015
    Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer
    Takakura K, Koido S, Kan S, Yoshida K, Mori M, Hirano Y, Ito Z, Kobayashi H, Takami S, Matsumoto Y, Kajihara M, Misawa T, Okamoto M, Sugiyama H, Homma S, Ohkusa T, Tajiri H. Anticancer research. 2015;35(1):555–562. PMID 25550602.
    PubMed
  32. Clinical studySame technology2015
    Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy
    Tsukinaga S, Kajihara M, Takakura K, Ito Z, Kanai T, Saito K, Takami S, Kobayashi H, Matsumoto Y, Odahara S, Uchiyama K, Arakawa H, Okamoto M, Sugiyama H, Sumiyama K, Ohkusa T, Koido S. World Journal of Gastroenterology. 2015;21(39):11168–11178. PMID 26494971.
    Full textPubMedDOI
  33. Case reportSame technology2015
    Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature
    Saito S, Yanagisawa R, Yoshikawa K, Higuchi Y, Koya T, Yoshizawa K, Tanaka M, Sakashita K, Kobayashi T, Kurata T, Hirabayashi K, Nakazawa Y, Shiohara M, Yonemitsu Y, Okamoto M, Sugiyama H, Koike K, Shimodaira S. Cytotherapy. 2015;17(3):330–335. PMID 25484308.
    PubMedDOI
  34. Clinical trialSame technology2014
    Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer
    Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, Tsukinaga S, Odahara S, Koyama S, Imazu H, Uchiyama K, Kajihara M, Arakawa H, Misawa T, Toyama Y, Yanagisawa S, Ikegami M, Kan S, Hayashi K, Komita H, Kamata Y, Ito M, Ishidao T, Yusa S, Shimodaira S, Gong J, Sugiyama H, Ohkusa T, Tajiri H. Clinical Cancer Research. 2014;20(16):4228–4239. PMID 25056373.
    PubMedDOI
  35. Clinical studySame technology2014
    Chemoimmunotherapy targeting Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer
    Koido S, Homma S, Okamoto M, Takakura K, Gong J, Sugiyama H, Ohkusa T, Tajiri H. Oncoimmunology. 2014;3(10):e958950. PMID 25941581.
    Full textPubMedDOI
  36. Clinical studyPeripheral research2014
    Prognostic significance of interleukin-8 and CD163-positive cell-infiltration in tumor tissues in patients with oral squamous cell carcinoma
    Fujita Y, Okamoto M, Goda H, Tano T, Nakashiro K, Sugita A, Fujita T, Koido S, Homma S, Kawakami Y, Hamakawa H. PloS one. 2014;9(12):e110378. PMID 25461761.
    Full textPubMedDOI
  37. Clinical studyPeripheral research2014
    Immunological assessment of cryotherapy in breast cancer patients
    Koido S, Kinoshita S, Mogami T, Kan S, Takakura K, Okamoto M, Homma S, Ohkusa T, Tajiri H, Harada J. Anticancer research. 2014;34(9):4869–4876. PMID 25202068.
    PubMed
  38. Basic researchComponent technology / related research2014
    Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine
    Ohtake J, Ohkuri T, Togashi Y, Kitamura H, Okuno K, Nishimura T. Immunology Letters. 2014;161(1):20–30. PMID 24794408.
    PubMedDOI
  39. Clinical studyComponent technology / related research2013
    Immunochemoradiotherapy for patients with oral squamous cell carcinoma: augmentation of OK-432-induced helper T cell 1 response by 5-FU and X-ray irradiation
    Tano T, Okamoto M, Kan S, Bando T, Goda H, Nakashiro K, Shimodaira S, Koido S, Homma S, Fujita T, Sato M, Yamashita N, Hamakawa H, Kawakami Y. Neoplasia (New York, N.Y.). 2013;15(7):805–814. PMID 23814492.
    Full textPubMedDOI
  40. Clinical studyComponent technology / related research2013
    Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma
    Tano T, Okamoto M, Kan S, Nakashiro K, Shimodaira S, Koido S, Homma S, Sato M, Fujita T, Kawakami Y, Hamakawa H. Neoplasia (New York, N.Y.). 2013;15(3):305–314. PMID 23479508.
    Full textPubMedDOI
  41. ReviewComponent technology / related research2013
    Immunotherapy for colorectal cancer
    Koido S, Ohkusa T, Homma S, Namiki Y, Takakura K, Saito K, Ito Z, Kobayashi H, Kajihara M, Uchiyama K, Arihiro S, Arakawa H, Okamoto M, Gong J, Tajiri H. World Journal of Gastroenterology. 2013;19(46):8531–8542. PMID 24379570.
    Full textPubMedDOI
  42. ReviewComponent technology / related research2013
    Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions
    Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Uchiyama K, Kajihara M, Arihiro S, Imazu H, Arakawa H, Kan S, Komita H, Kamata Y, Ito M, Ohkusa T, Gong J, Tajiri H. Oncoimmunology. 2013;2(9):e25994. PMID 24228229.
    Full textPubMedDOI
  43. ReviewComponent technology / related research2013
    Fusions between dendritic cells and whole tumor cells as anticancer vaccines
    Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Uchiyama K, Kajihara M, Arihiro S, Imazu H, Arakawa H, Kan S, Komita H, Ito M, Ohkusa T, Gong J, Tajiri H. Oncoimmunology. 2013;2(5):e24437. PMID 23762810.
    Full textPubMedDOI
  44. Clinical studySame technology2012
    Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma
    Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S, Koido S, Homma S, Okamoto M. Pancreas. 2012;41(2):195–205. PMID 21792083.
    PubMedDOI
  45. Case reportComponent technology / related research2012
    First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen
    Takahashi N, Ohkuri T, Homma S, Ohtake J, Wakita D, Togashi Y, Kitamura H, Todo S, Nishimura T. Cancer Science. 2012;103(1):150–153. PMID 22221328.
    Full textPubMedDOI
  46. Basic researchPeripheral research2012
    Neuropeptide signaling activates dendritic cell-mediated type 1 immune responses through neurokinin-2 receptor
    Kitamura H, Kobayashi M, Wakita D, Nishimura T. Journal of immunology (Baltimore, Md. : 1950). 2012;188(9):4200–4208. PMID 22474018.
    PubMedDOI
  47. ReviewComponent technology / related research2012
    [The regulation of antitumor immune responses by helper T cells--From the bench research to the discovery of H/K-HELP cancer vaccine]
    Nishimura T. Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology. 2012;35(5):412–423. PMID 23124083. In Japanese.
    PubMedDOI
  48. Clinical trialComponent technology / related research2007
    Results of a phase I clinical study using dendritic cell vaccinations for thyroid cancer
    Kuwabara K, Nishishita T, Morishita M, Oyaizu N, Yamashita S, Kanematsu T, Obara T, Mimura Y, Inoue Y, Kaminishi M, Kaga K, Amino N, Kitaoka M, Ito K, Miyauchi A, Noguchi S, Uchimaru K, Akagawa E, Watanabe N, Takahashi TA, Sato K, Inazawa T, Nakaoka T, Yamashita N. Thyroid. 2007;17(1):53–58. PMID 17274750.
    PubMedDOI
  49. Clinical studyComponent technology / related research2006
    [The relationship between gene expression of Bcl-2 and Bax and the therapeutic effect in oral cancer patients]
    Oshikawa T, Okamoto M, Ahmed SU, Tano T, Sato M. Gan to kagaku ryoho. Cancer & chemotherapy. 2006;33(12):1723–1725. PMID 17212087. In Japanese.
    PubMed
  50. Clinical studyPeripheral research2006
    Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance
    Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, Miyamoto M, Morikawa T, Kondo S, Ikeda H, Nishimura T. International journal of oncology. 2006;28(5):1089–1098. PMID 16596224.
    PubMed
  51. Clinical trialComponent technology / related research2004
    Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
    Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, Hosen N, Yoshihara S, Wu F, Fujiki F, Murakami M, Masuda T, Nishida S, Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S, Kawase I, Sugiyama H. Proceedings of the National Academy of Sciences of the USA. 2004;101(38):13885–13890. PMID 15365188.
    Full textPubMedDOI
  52. ReviewComponent technology / related research2004
    Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy
    Ryoma Y, Moriya Y, Okamoto M, Kanaya I, Saito M, Sato M. Anticancer research. 2004;24(5C):3295–3301. PMID 15515424.
    PubMed
  53. ReviewComponent technology / related research2004
    The critical role of type-1 innate and acquired immunity in tumor immunotherapy
    Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T. Cancer Science. 2004;95(9):697–703. PMID 15471553.
    Full textPubMedDOI
  54. Clinical trialComponent technology / related research2003
    Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2
    Nagayama H, Sato K, Morishita M, Uchimaru K, Oyaizu N, Inazawa T, Yamasaki T, Enomoto M, Nakaoka T, Nakamura T, Maekawa T, Yamamoto A, Shimada S, Saida T, Kawakami Y, Asano S, Tani K, Takahashi TA, Yamashita N. Melanoma Research. 2003;13(5):521–530. PMID 14512794.
    PubMedDOI
  55. ReviewComponent technology / related research2003
    Toll-like receptor signaling in anti-cancer immunity
    Okamoto M, Sato M. The journal of medical investigation : JMI. 2003;50(1-2):9–24. PMID 12630564.
    PubMed

The listed studies include case reports, small series, retrospective analyses and animal experiments and do not establish treatment efficacy. The full archive, including basic research, is on the Japanese page 学術実績. Treatment outcomes vary between individuals and the same results cannot be expected for every patient.